Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Public ClinicalTrials.gov record NCT02898454. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Study identification
- NCT ID
- NCT02898454
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 448 participants
Conditions and interventions
Interventions
- Dupilumab SAR231893 (REGN668) Drug
- Placebo Drug
- Mometasone furoate nasal spray Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2016
- Primary completion
- Aug 26, 2018
- Completion
- Nov 15, 2018
- Last update posted
- Oct 22, 2019
2016 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400019 | Birmingham | Alabama | 35209 | — |
| Investigational Site Number 8400011 | Fresno | California | 93720 | — |
| Investigational Site Number 8400008 | Huntington Beach | California | 92647 | — |
| Investigational Site Number 8400004 | Rolling Hills Estates | California | 90274 | — |
| Investigational Site Number 8400012 | Walnut Creek | California | 94598 | — |
| Investigational Site Number 8400017 | Colorado Springs | Colorado | 80909 | — |
| Investigational Site Number 8400006 | Denver | Colorado | 80230 | — |
| Investigational Site Number 8400022 | New Haven | Connecticut | 06519 | — |
| Investigational Site Number 8400002 | Louisville | Kentucky | 40207 | — |
| Investigational Site Number 8400021 | Boston | Massachusetts | 02114 | — |
| Investigational Site Number 8400014 | Kansas City | Missouri | 64114 | — |
| Investigational Site Number 8400024 | The Bronx | New York | 10461 | — |
| Investigational Site Number 8400016 | North Charleston | North Carolina | 29420 | — |
| Investigational Site Number 8400013 | Bethlehem | Pennsylvania | 18017 | — |
| Investigational Site Number 8400005 | Philadelphia | Pennsylvania | 19104 | — |
| Investigational Site Number 8400003 | Pittsburgh | Pennsylvania | 15213 | — |
| Investigational Site Number 8400009 | Salt Lake City | Utah | 84132 | — |
| Investigational Site Number 8400010 | Bellevue | Washington | 98225 | — |
| Investigational Site Number 8400007 | Milwaukee | Wisconsin | 53219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02898454, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02898454 live on ClinicalTrials.gov.